KREBSBIO - Krebs Biochem
📢 Recent Corporate Announcements
Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.
- Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.
- Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.
- Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.
- The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.
- Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.
Krebs Biochemicals and Industries Limited has submitted its monthly report regarding the re-lodgement of transfer requests for physical shares as per SEBI guidelines. For the month ending December 31, 2025, the company's Registrar, KFIN Technologies, reported that zero requests were received or processed. This disclosure is part of a special six-month window mandated by SEBI which ran from July 7, 2025, to January 6, 2026. The filing is a routine regulatory update and does not impact the company's financial or operational standing.
- Zero (NIL) requests received for re-lodgement of physical share transfers during December 2025.
- Compliance follows SEBI Circular SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025.
- The special window for physical share transfer re-lodgement was active from July 7, 2025, to January 6, 2026.
- KFIN Technologies Limited confirmed the status as the company's Registrar and Share Transfer Agent.
Krebs Biochemicals has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ending December 31, 2025. The document confirms that KFIN Technologies Limited, the company's Registrar and Share Transfer Agent, has processed all dematerialization and rematerialization requests. These details have been duly reported to both the BSE and NSE. This filing is a mandatory procedural requirement to ensure accurate shareholding records across depositories.
- Compliance certificate issued for the quarter ended December 31, 2025.
- KFIN Technologies Limited confirmed processing of demat and remat requests.
- Filing covers requirements for both NSDL and CDSL depositories.
- The company is listed on both BSE (524518) and NSE (KREBSBIO).
Krebs Biochemicals and Industries Limited has announced the closure of its trading window starting from the close of business hours on December 31, 2025. This move is in compliance with SEBI Insider Trading regulations ahead of the declaration of unaudited financial results for the third quarter and nine months ending December 31, 2025. The restriction applies to all promoters, directors, and designated persons. The trading window will remain closed until 48 hours after the financial results are officially declared to the stock exchanges.
- Trading window closure effective from the close of business hours on December 31, 2025.
- Closure pertains to the upcoming declaration of Q3 and nine-month financial results for the period ending Dec 31, 2025.
- Restriction applies to promoters, directors, designated persons, and their immediate relatives.
- The window will reopen 48 hours after the financial results are made public.
- The specific date for the Board meeting to consider results will be announced in due course.
Krebs Biochemicals and Industries Limited has announced the receipt of a report from KFIN Technologies Limited regarding the re-lodgement of transfer requests for physical shares as of November 30, 2025, in compliance with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025. During the month, the number of requests received, processed, approved, and rejected was NIL. The special window for re-lodgement is open from July 7, 2025, until January 6, 2026. Shareholders can find the notice on the company website.
- SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated 2nd July 2025
- Special window open from July 7, 2025 till January 6, 2026
- No. of requests received during the month: NIL
- Report as of November 30, 2025
Financial Performance
Revenue Growth by Segment
Total revenue from operations fell 14.1% YoY to INR 43.31 Cr in FY25 from INR 50.42 Cr in FY24. Segment-specific growth percentages are not disclosed in available documents.
Profitability Margins
Net margin is deeply negative at -62.1% for FY25, worsening from -39.1% in FY24. The company incurred a net loss of INR 26.92 Cr in FY25, which widened by 36.5% compared to the INR 19.73 Cr loss in FY24 due to declining revenue and rising finance costs.
EBITDA Margin
EBITDA margin is negative at -33.1% for FY25. Core profitability is under severe pressure as total expenses of INR 70.94 Cr significantly exceed total income of INR 44.02 Cr.
Capital Expenditure
Property, Plant and Equipment stood at INR 145.23 Cr as of March 31, 2025. Capital Work in Progress (CWIP) increased to INR 1.24 Cr from INR 0.16 Cr, indicating minor ongoing investments.
Credit Rating & Borrowing
Borrowing costs (finance costs) increased by 26.1% YoY to INR 5.91 Cr in FY25 from INR 4.69 Cr in FY24. Specific credit ratings and interest rate percentages are not disclosed in available documents.
Operational Drivers
Capacity Expansion
Current installed capacity is not disclosed. The company plans to achieve break-even through the addition of new products being manufactured, supported by the Principal Promoter Shareholder.
Raw Material Costs
Cost of materials consumed was INR 2.49 Cr in FY25, representing 5.7% of revenue. This was a 54.1% decrease from INR 5.43 Cr in FY24, likely due to reduced production volumes.
Strategic Growth
Growth Strategy
The company aims to achieve break-even by adding new products to its manufacturing portfolio and leveraging marketing and financial support from its Principal Promoter Shareholder. The promoter has provided a confirmation of financial support to meet obligations and turnaround operations.
Products & Services
Biochemical products and API intermediates developed through biochemistry processes.
New Products/Services
Management plans to add new products to the manufacturing line to drive a turnaround, though specific revenue contribution percentages are not disclosed.
Strategic Alliances
The company relies on a strategic support arrangement with its Principal Promoter Shareholder for financial needs and marketing support.
External Factors
Industry Trends
The industry is characterized by cyclical demand and pricing. The company is positioning itself for a turnaround by diversifying its product range and relying on promoter-backed marketing support to navigate competitive capacity increases.
Competitive Landscape
The company faces significant competition from players with increased installed capacity, which impacts pricing and market share.
Competitive Moat
The company's moat is not clearly established in the documents, as it currently faces material uncertainty regarding its ability to continue as a going concern due to a negative net worth of INR 146.24 Cr.
Macro Economic Sensitivity
The business is highly sensitive to the global economy and cyclical demand for biochemical products. Any global incident affecting world markets directly impacts operations.
Geopolitical Risks
Geopolitical risks and world market incidents are cited as factors that could materially affect the company's operations and financial presumptions.
Regulatory & Governance
Industry Regulations
Operations are subject to changes in government regulations and tax regimes, which can materially affect financial performance.
Legal Contingencies
The company has disclosed the impact of pending litigations on its financial position in Note 32 of the standalone financial statements. Specific case values are not provided in the summary.
Risk Analysis
Key Uncertainties
The primary uncertainty is the 'Going Concern' status. Total liabilities exceeded total assets by INR 146.24 Cr as of March 31, 2025 (up from INR 119.22 Cr in FY24), creating a material uncertainty about the company's survival without continuous promoter support.
Third Party Dependencies
High dependency on the Principal Promoter Shareholder for financial liquidity and marketing support to continue operations.
Credit & Counterparty Risk
Trade receivables dropped by 97.4% to INR 0.05 Cr in FY25 from INR 1.90 Cr in FY24, which may indicate a shift in credit terms or a significant reduction in credit-based sales.